SG11202102483SA - Combination therapy for the treatment of triple-negative breast cancer - Google Patents
Combination therapy for the treatment of triple-negative breast cancerInfo
- Publication number
- SG11202102483SA SG11202102483SA SG11202102483SA SG11202102483SA SG11202102483SA SG 11202102483S A SG11202102483S A SG 11202102483SA SG 11202102483S A SG11202102483S A SG 11202102483SA SG 11202102483S A SG11202102483S A SG 11202102483SA SG 11202102483S A SG11202102483S A SG 11202102483SA
- Authority
- SG
- Singapore
- Prior art keywords
- triple
- treatment
- breast cancer
- combination therapy
- negative breast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730879P | 2018-09-13 | 2018-09-13 | |
| US201862737628P | 2018-09-27 | 2018-09-27 | |
| PCT/IB2019/001009 WO2020053655A1 (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of triple-negative breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102483SA true SG11202102483SA (en) | 2021-04-29 |
Family
ID=69777478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102483SA SG11202102483SA (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of triple-negative breast cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11607405B2 (en) |
| EP (1) | EP3849549A4 (en) |
| JP (1) | JP2022500435A (en) |
| KR (1) | KR20210087440A (en) |
| CN (1) | CN112912077B (en) |
| AU (1) | AU2019337470A1 (en) |
| CA (1) | CA3111371A1 (en) |
| IL (1) | IL281256A (en) |
| MX (1) | MX2021002886A (en) |
| SG (1) | SG11202102483SA (en) |
| TW (1) | TWI816881B (en) |
| WO (1) | WO2020053655A1 (en) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2935860T3 (en) | 2015-04-10 | 2023-03-13 | Spatial Transcriptomics Ab | Multiplex, spatially distinguished nucleic acid analysis of biological specimens |
| FI3891300T3 (en) | 2019-12-23 | 2023-05-10 | 10X Genomics Inc | Methods for spatial analysis using rna-templated ligation |
| CN115715329A (en) | 2020-01-10 | 2023-02-24 | 10X基因组学有限公司 | Method for determining the position of a target nucleic acid in a biological sample |
| US11702693B2 (en) | 2020-01-21 | 2023-07-18 | 10X Genomics, Inc. | Methods for printing cells and generating arrays of barcoded cells |
| US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
| US11821035B1 (en) | 2020-01-29 | 2023-11-21 | 10X Genomics, Inc. | Compositions and methods of making gene expression libraries |
| US11898205B2 (en) | 2020-02-03 | 2024-02-13 | 10X Genomics, Inc. | Increasing capture efficiency of spatial assays |
| US11732300B2 (en) | 2020-02-05 | 2023-08-22 | 10X Genomics, Inc. | Increasing efficiency of spatial analysis in a biological sample |
| US11835462B2 (en) | 2020-02-11 | 2023-12-05 | 10X Genomics, Inc. | Methods and compositions for partitioning a biological sample |
| US11891654B2 (en) | 2020-02-24 | 2024-02-06 | 10X Genomics, Inc. | Methods of making gene expression libraries |
| US11768175B1 (en) | 2020-03-04 | 2023-09-26 | 10X Genomics, Inc. | Electrophoretic methods for spatial analysis |
| ES2965354T3 (en) | 2020-04-22 | 2024-04-12 | 10X Genomics Inc | Methods for spatial analysis using targeted RNA deletion |
| CN116134308A (en) | 2020-05-19 | 2023-05-16 | 10X基因组学有限公司 | Electrophoresis cartridge and instrument |
| EP4153775A1 (en) | 2020-05-22 | 2023-03-29 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
| WO2021237056A1 (en) | 2020-05-22 | 2021-11-25 | 10X Genomics, Inc. | Rna integrity analysis in a biological sample |
| AU2021275906A1 (en) | 2020-05-22 | 2022-12-22 | 10X Genomics, Inc. | Spatial analysis to detect sequence variants |
| WO2021242834A1 (en) | 2020-05-26 | 2021-12-02 | 10X Genomics, Inc. | Method for resetting an array |
| CN116249785A (en) | 2020-06-02 | 2023-06-09 | 10X基因组学有限公司 | Space transcriptomics for antigen-receptor |
| EP4025692A2 (en) | 2020-06-02 | 2022-07-13 | 10X Genomics, Inc. | Nucleic acid library methods |
| EP4162074B1 (en) | 2020-06-08 | 2024-04-24 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
| WO2021252591A1 (en) | 2020-06-10 | 2021-12-16 | 10X Genomics, Inc. | Methods for determining a location of an analyte in a biological sample |
| US20230279474A1 (en) | 2020-06-10 | 2023-09-07 | 10X Genomics, Inc. | Methods for spatial analysis using blocker oligonucleotides |
| CN116034166A (en) | 2020-06-25 | 2023-04-28 | 10X基因组学有限公司 | Spatial analysis of DNA methylation |
| US11761038B1 (en) | 2020-07-06 | 2023-09-19 | 10X Genomics, Inc. | Methods for identifying a location of an RNA in a biological sample |
| WO2022025965A1 (en) | 2020-07-31 | 2022-02-03 | 10X Genomics, Inc. | De-crosslinking compounds and methods of use for spatial analysis |
| US11981958B1 (en) | 2020-08-20 | 2024-05-14 | 10X Genomics, Inc. | Methods for spatial analysis using DNA capture |
| CN116547388A (en) | 2020-09-15 | 2023-08-04 | 10X基因组学有限公司 | Method for releasing extended capture probes from a substrate and use thereof |
| WO2022060953A1 (en) | 2020-09-16 | 2022-03-24 | 10X Genomics, Inc. | Methods of determining the location of an analyte in a biological sample using a plurality of wells |
| US11926822B1 (en) | 2020-09-23 | 2024-03-12 | 10X Genomics, Inc. | Three-dimensional spatial analysis |
| WO2022109181A1 (en) | 2020-11-18 | 2022-05-27 | 10X Genomics, Inc. | Methods and compositions for analyzing immune infiltration in cancer stroma to predict clinical outcome |
| US11827935B1 (en) | 2020-11-19 | 2023-11-28 | 10X Genomics, Inc. | Methods for spatial analysis using rolling circle amplification and detection probes |
| WO2022140028A1 (en) | 2020-12-21 | 2022-06-30 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing probes and/or barcodes |
| US20240068017A1 (en) | 2020-12-30 | 2024-02-29 | 10X Genomics, Inc. | Methods for analyte capture determination |
| EP4301870A1 (en) | 2021-03-18 | 2024-01-10 | 10X Genomics, Inc. | Multiplex capture of gene and protein expression from a biological sample |
| WO2022226057A1 (en) | 2021-04-20 | 2022-10-27 | 10X Genomics, Inc. | Methods for assessing sample quality prior to spatial analysis using templated ligation |
| WO2022271820A1 (en) | 2021-06-22 | 2022-12-29 | 10X Genomics, Inc. | Spatial detection of sars-cov-2 using templated ligation |
| EP4370675A1 (en) | 2021-08-12 | 2024-05-22 | 10X Genomics, Inc. | Methods, compositions and systems for identifying antigen-binding molecules |
| EP4196605A1 (en) | 2021-09-01 | 2023-06-21 | 10X Genomics, Inc. | Methods, compositions, and kits for blocking a capture probe on a spatial array |
| TW202327594A (en) * | 2021-09-23 | 2023-07-16 | 大陸商恒翼生物醫藥（上海）股份有限公司 | Methods for treating triple-negative breast cancer in pre-selected patient populations with a combination of a bet bromodomain inhibitor and a parp inhibitor |
| WO2023102313A1 (en) | 2021-11-30 | 2023-06-08 | 10X Genomics, Inc. | Systems and methods for identifying regions of aneuploidy in a tissue |
| EP4305195A2 (en) | 2021-12-01 | 2024-01-17 | 10X Genomics, Inc. | Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis |
| WO2023150163A1 (en) | 2022-02-01 | 2023-08-10 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing analytes from lymphatic tissue |
| WO2023150171A1 (en) | 2022-02-01 | 2023-08-10 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing analytes from glioblastoma samples |
| US20230306593A1 (en) | 2022-02-15 | 2023-09-28 | 10X Genomics, Inc. | Systems and methods for spatial analysis of analytes using fiducial alignment |
| WO2023215552A1 (en) | 2022-05-06 | 2023-11-09 | 10X Genomics, Inc. | Molecular barcode readers for analyte detection |
| WO2023229982A2 (en) | 2022-05-24 | 2023-11-30 | 10X Genomics, Inc. | Porous structure confinement for convection suppression |
| WO2023250077A1 (en) | 2022-06-22 | 2023-12-28 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing probes and/or barcodes |
| WO2024035844A1 (en) | 2022-08-12 | 2024-02-15 | 10X Genomics, Inc. | Methods for reducing capture of analytes |
| WO2024081212A1 (en) | 2022-10-10 | 2024-04-18 | 10X Genomics, Inc. | In vitro transcription of spatially captured nucleic acids |
| WO2024086167A2 (en) | 2022-10-17 | 2024-04-25 | 10X Genomics, Inc. | Methods, compositions, and kits for determining the location of an analyte in a biological sample |
| WO2024102809A1 (en) | 2022-11-09 | 2024-05-16 | 10X Genomics, Inc. | Methods, compositions, and kits for determining the location of multiple analytes in a biological sample |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2702699A1 (en) * | 2007-10-18 | 2009-04-23 | Novartis Ag | Csf-1r inhibitors compositions, and mthods of use |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| CN104736144B (en) * | 2012-07-27 | 2019-02-01 | 艾祖米科技有限公司 | Outlet inhibitor combination and the method treated using this composition |
| WO2014128655A1 (en) * | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| WO2015002754A2 (en) * | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
| MX2016007433A (en) * | 2013-12-10 | 2016-09-13 | Abbvie Inc | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer. |
| US10813939B2 (en) * | 2014-12-05 | 2020-10-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| WO2017015027A1 (en) * | 2015-07-20 | 2017-01-26 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN108289957A (en) * | 2015-10-02 | 2018-07-17 | 达纳-法伯癌症研究所股份有限公司 | The combination treatment that bromodomain inhibitor and checkpoint block |
| US20180141939A1 (en) * | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
-
2019
- 2019-09-12 TW TW108133140A patent/TWI816881B/en active
- 2019-09-13 EP EP19859446.7A patent/EP3849549A4/en not_active Withdrawn
- 2019-09-13 AU AU2019337470A patent/AU2019337470A1/en active Pending
- 2019-09-13 CN CN201980059875.XA patent/CN112912077B/en active Active
- 2019-09-13 WO PCT/IB2019/001009 patent/WO2020053655A1/en unknown
- 2019-09-13 SG SG11202102483SA patent/SG11202102483SA/en unknown
- 2019-09-13 US US17/275,458 patent/US11607405B2/en active Active
- 2019-09-13 KR KR1020217010521A patent/KR20210087440A/en active Search and Examination
- 2019-09-13 CA CA3111371A patent/CA3111371A1/en active Pending
- 2019-09-13 JP JP2021514091A patent/JP2022500435A/en active Pending
- 2019-09-13 MX MX2021002886A patent/MX2021002886A/en unknown
-
2021
- 2021-03-04 IL IL281256A patent/IL281256A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202027746A (en) | 2020-08-01 |
| CN112912077A (en) | 2021-06-04 |
| JP2022500435A (en) | 2022-01-04 |
| CN112912077B (en) | 2023-04-04 |
| TWI816881B (en) | 2023-10-01 |
| US20220062246A1 (en) | 2022-03-03 |
| CA3111371A1 (en) | 2020-03-19 |
| WO2020053655A1 (en) | 2020-03-19 |
| US11607405B2 (en) | 2023-03-21 |
| KR20210087440A (en) | 2021-07-12 |
| EP3849549A4 (en) | 2022-06-08 |
| AU2019337470A1 (en) | 2021-03-25 |
| IL281256A (en) | 2021-04-29 |
| EP3849549A1 (en) | 2021-07-21 |
| MX2021002886A (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281256A (en) | Combination therapy for the treatment of triple-negative breast cancer | |
| IL280707A (en) | Diagnostic and therapeutic methods for the treatment of breast cancer | |
| IL267795A (en) | Combination therapy for the treatment of cancer | |
| RS64472B1 (en) | Combination therapy for the treatment or prevention of tumours | |
| IL276398A (en) | Combination therapy for the treatment of mastocytosis | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| IL280337A (en) | Lag-3 combination therapy for the treatment of cancer | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL284162A (en) | Combination therapy for the treatment of cancer | |
| IL269357A (en) | Combination therapies for the treatment of breast cancer | |
| SG11202011117VA (en) | Treatment of cancer | |
| IL281439A (en) | Combination therapy for treating blood cancer | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| IL266993A (en) | Combination therapy for the treatment of cancer | |
| IL281281A (en) | Combination therapy for the treatment of prostate cancer | |
| IL279277A (en) | In vivo controlled combination therapy for treatment of cancer | |
| IL263905A (en) | Combination therapy of cancer | |
| IL275981A (en) | Combination therapies for the treatment of breast cancer | |
| SG11202100571TA (en) | Anti-lypd3 car t-cell therapy for the treatment of cancer | |
| IL253642A0 (en) | Combination therapy for the treatment of cancer | |
| IL282471A (en) | Combination immunotherapy for treatment of triple-negative breast cancer | |
| IL281782A (en) | Pharmaceutical combination for the treatment of cancer | |
| EP3849550A4 (en) | Combination therapy for the treatment of estrogen-receptor positive breast cancer | |
| IL268897A (en) | Medicament for malignant tumor treatment |